Gemox: a widely useful therapy against solid tumors-review and personal experience.
Gemcitabine and oxaliplatin have been demonstrated to have synergistic activity in several human cancer cell lines and varying patterns of toxicity. Gemcitabine is a very well tolerated drug with mild myelosuppression, asthenia and nausea/vomiting as its main toxicities. On the other hand, cumulative peripheral neurotoxicity is the main side effect of oxaliplatin. Therefore, there is a strong preclinical rationale to combine gemcitabine and oxaliplatin (Gemox) and to test this regimen as an alternative approach to gemcitabine with cisplatin or carboplatin as a treatment for different tumors. By reviewing the literature we found that the Gemox regimen seems to be active in the treatment of various kinds of tumors and is well tolerated. Further studies, especially to determine the optimal schedule, are clearly warranted. In addition, we report here our single-institution experience with this combination as salvage treatment for heavily pretreated cancer patients.
Unità Operativa di Oncologia, Fondazione Poliambulanza, Brescia, Italy.
F
F
Meriggi
A
A
Zaniboni
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D004357:Drug Synergism; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D016879:Salvage Therapy; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000093542:Gemcitabine